158.17
Overview
News
Price History
Option Chain
Financials
Why BDX Down?
Discussions
Forecast
Stock Split
Dividend History
Becton Dickinson Co stock is traded at $158.17, with a volume of 2.09M.
It is down -1.10% in the last 24 hours and up +11.69% over the past month.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
See More
Previous Close:
$159.93
Open:
$158.84
24h Volume:
2.09M
Relative Volume:
0.74
Market Cap:
$43.58B
Revenue:
$21.37B
Net Income/Loss:
$1.41B
P/E Ratio:
40.11
EPS:
3.9437
Net Cash Flow:
$3.07B
1W Performance:
+4.10%
1M Performance:
+11.69%
6M Performance:
-23.63%
1Y Performance:
-12.56%
Becton Dickinson Co Stock (BDX) Company Profile
Name
Becton Dickinson Co
Sector
Industry
Phone
(201) 847-6800
Address
ONE BECTON DR, FRANKLIN LAKES
Compare BDX vs ISRG, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BDX
Becton Dickinson Co
|
158.17 | 44.07B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ISRG
Intuitive Surgical Inc
|
345.42 | 142.49B | 10.58B | 3.00B | 2.83B | 8.2437 |
|
ALC
Alcon Inc
|
70.26 | 34.44B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
39.79 | 34.76B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
198.99 | 29.41B | 5.54B | 1.52B | 1.74B | 10.37 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Resumed | Goldman | Neutral |
| Feb-10-26 | Resumed | Barclays | Overweight |
| Feb-03-26 | Resumed | Citigroup | Buy |
| Sep-25-25 | Initiated | RBC Capital Mkts | Sector Perform |
| May-22-25 | Downgrade | Citigroup | Buy → Neutral |
| May-02-25 | Downgrade | Goldman | Buy → Neutral |
| May-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-01-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-24-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| May-05-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-12-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jan-03-23 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-22 | Upgrade | Citigroup | Sell → Neutral |
| Jul-11-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-24-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-18-22 | Resumed | Raymond James | Mkt Perform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-08-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-09-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-01-20 | Resumed | Goldman | Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-07-20 | Downgrade | Cowen | Outperform → Market Perform |
| Feb-07-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Feb-07-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Feb-06-20 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-08-20 | Downgrade | Barclays | Overweight → Equal Weight |
| May-13-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-07-18 | Initiated | Deutsche Bank | Buy |
| Oct-16-18 | Initiated | Barclays | Equal Weight |
| Jun-21-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Jan-19-18 | Resumed | BofA/Merrill | Buy |
| Jan-05-18 | Upgrade | Citigroup | Sell → Neutral |
| Jan-05-18 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Dec-29-17 | Reiterated | Deutsche Bank | Buy |
View All
Becton Dickinson Co Stock (BDX) Latest News
Becton Dickinson & Co. stock underperforms Friday when compared to competitors - MarketWatch
Becton Dickinson (BDX) Stock Looks Cheap On Cash Flow Yet Fair On Earnings - simplywall.st
Becton Dickinson & Co (BDX) Shares Surge 3.3% -- What GF Score o - GuruFocus
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Becton Dickinson stock holds steady as medical technology demand underpins long-term growth - ad-hoc-news.de
Becton Dickinson & Co. stock underperforms Tuesday when compared to competitors - MarketWatch
BDX.GE Bond Profile — Key Metrics - TradingView
Goldman Sachs Adjusts Price Target on Becton, Dickinson and Company to $152 From $150, Maintains Neutral Rating - Moomoo
US75887CK3 Bond Profile — Key Metrics - TradingView
XS276302639 Bond Profile — Key Metrics - TradingView
RBC Capital Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Maintains Target Price $175 - Moomoo
XS283900436 Bond Profile — Key Metrics - TradingView
Becton, Dickinson and Company (BDX) Stock Analysis: A 16% Upside Opportunity in the Healthcare Sector - DirectorsTalk Interviews
BD Korea expands BD Aptra portfolio with launch of single-use digital flexible cystoscope in Korea - koreabiomed.com
Becton, Dickinson and Company stock: Is BDX underperforming the healthcare sector? - MSN
Evercore Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $180 - 富途牛牛
Becton Dickinson & Co highlights its medical technology footprint as a global healthcare supplier - Ad Hoc News
A Look at Becton Dickinson & Co (BDX) After 3.7% Decline -- GF V - GuruFocus
Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Becton Dickinson (BDX) Following Its Veritor Shift And Index Changes Looks Undervalued - simplywall.st
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom - The Motley Fool
Becton, Dickinson and (NYSE:BDX) Releases FY23 Earnings Guidance - 富途牛牛
Becton Dickinson and Co steadies operations as healthcare demand evolves - ad-hoc-news.de
Form 4 Becton Dickinson and Co For: 6 July By Investing.com - Investing.com India
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Evercore ISI Adjusts Price Target on Becton, Dickinson and Company to $180 From $190 - Moomoo
Becton, Dickinson and Company (BDX) Stock Analysis: Evaluating Growth Potential and Analyst Ratings - DirectorsTalk Interviews
Does Vizient’s CentroVena One Deal and Index Shuffle Change The Bull Case For Becton Dickinson (BDX)? - simplywall.st
Becton Dickinson stock gains after company lifts earnings outlook By Investing.com - Investing.com Nigeria
Becton Dickinson & Co (BDX) Stock Forum and Discussion - Moomoo
Becton Dickinson stock holds its setup. Focus shifts to business fundamentals. - AD HOC NEWS
Is It Too Late to Buy Becton Dickinson & Co (BDX) After 3.4% Ral - GuruFocus
Becton Dickinson holds steady as investors await a fresh catalyst - AD HOC NEWS
Becton, Dickinson and Company: Now Is A Great Time To Buy (NYSE:BDX) - Seeking Alpha
Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
BD (BDX) Receives Vizient Innovative Technology Contract for CentroVena One Insertion System - Insider Monkey
List of 36 Acquisitions by Becton Dickinson (Jul 2026) - Tracxn
Becton Dickinson (NYSE:BDX) Advances in NYSE Composite After Vizient Deal - Kalkine Media
Becton Dickinson (BDX) Wins Vizient Contract As Fair Value Stays In Focus - simplywall.st
Becton Dickinson updates fiscal 2026 outlook, shares steady after cautious guidance - AD HOC NEWS
Form 4 Becton Dickinson and Co For: 26 June By Investing.com - Investing.com India
Insider Sell: Michael Feld Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
Michael Feld sells $11,460 of Becton Dickinson stock - Investing.com
Becton Dickinson & Co (BDX) Stock Up 3.0% and Still Undervalued -- GF Score: 76/100 - GuruFocus
Becton Dickinson EVP sells $160,226 in BDX shares By Investing.com - Investing.com South Africa
Becton Dickinson EVP sells $160,226 in BDX shares - Investing.com UK
AQR Trend Total Return Fund's Becton Dickinson & Co(BDX) Holding History - GuruFocus
Form 4 Becton Dickinson and Co For: 25 June By Investing.com - Investing.com Australia
Insider Sell: Michael Garrison Sells 1,100 Shares of Becton Dick - GuruFocus
Becton Dickinson Co Stock (BDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):